SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

(2017) Ajay Gupta et al.   LANCET

Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia

(2016) Htet Khine et al.   AMERICAN HEART JOURNAL

Association between SLCO1B1 −521T>C and −388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis

(2016) Jiajia Jiang et al.   SpringerPlus

Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States

(2015) Bruce K. Birmingham et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?

(2015) Bruce K. Birmingham et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk

(2015) Qingtao Hou et al.   MEDICINE

Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2

(2014) Marco Ferrari et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort

(2014) Joseph P. Kitzmiller et al.   Pharmacogenetics and Genomics

Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies

(2014) Dhiaa A. Taha et al.   Translational Research

Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy

(2013) Jacqueline S. Danik et al.   AMERICAN HEART JOURNAL

Narrative Review: Statin-Related Myopathy

(2013) Tisha R. Joy   ANNALS OF INTERNAL MEDICINE

Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care

(2013) Marianne K. DeGorter et al.   Circulation-Cardiovascular Genetics

SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink

(2013) D F Carr et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study

(2013) Catherine E. de Keyser et al.   Pharmacogenetics and Genomics

Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients

(2013) Hon-Kit Lee et al.   PHARMACOGENOMICS

Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1

(2013) Anne T Nies et al.   Genome Medicine

Is there clinical benefit to routine enzyme testing of patients on statins?

(2011) Asher Elhayany et al.   Expert Opinion On Drug Safety

Prevalence and risk factors of muscle complications secondary to statins

(2011) Khalid El-Salem et al.   MUSCLE & NERVE

Genetic involvement in statins induced myopathy. Preliminary data from an observational case–control study

(2010) Luca Puccetti et al.   ATHEROSCLEROSIS

Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study

(2010) L A Donnelly et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects

(2009) Deepak Voora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE